APTX News and Press, Aptinyx Inc. From 08/12/22

Aptinyx ( NASDAQ: APTX ) said its oral medicine NYX-2925 did not show statistically significant separation from placebo in reducing pain, failing to meet the main goal of a phase 2b trial. The study evaluated 2 doses (50mg-100mg) of the drug versus placebo in...

NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical st...

Aptinyx Inc. (APTX) Q2 2022 Earnings Conference Call August 04, 2022 05:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - President & Chief Executive Officer Ashish Khanna - Chief Financi...

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q2 2022 Earnings Call Aug 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q2 2022 Earnings Call Transcript

Aptinyx press release ( NASDAQ: APTX ): Q2 GAAP EPS of -$0.26 beats by $0.02 . Shares +6% . Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q...

Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million ...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET ...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1 st Annual Mental Health Conference. The conference...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022....

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be p...